Domestic Pharma, Bio Firms Unveil R&D Results Through Clinical and Academic Presentations

The R&D achievements of domestic pharmaceutical and biotechnology companies are shining in the global market. These industry trends are concretely confirmed by recent presentations at overseas academic conferences and capital invested in the expansion of domestic research facilities.

Shinrazen unveiled clinical data for its self-developed anti-cancer drug candidate 'BAL0891' at the American Association for Cancer Research (AACR). Through this, the company presented a biomarker capable of overcoming the limitations of its existing anti-cancer drug, PexaVec.

Jeil Pharmaceutical is bolstering the profitability of its core pipeline asset 'Jequvo' by shifting its narrative from a 'commodity' to a 'product' strategy.

Meanwhile, Dong-A ST is concurrently streamlining management, having achieved an integrated ESG rating of 'A' through improvements in its governance structure.